Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
EVO is expected to report earnings to fall 44.37% to -5 cents per share on August 13
Q2'25
Est.
$-0.06
Q1'25
Missed
by $0.09
Q4'24
Missed
by $0.09
Q3'24
Est.
$-0.12
Q2'24
Missed
by $0.26
The last earnings report on May 06 showed earnings per share of -10 cents, missing the estimate of -1 cents. With 11.66K shares outstanding, the current market capitalization sits at 2.77B.